X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AVD-104 is a novel small molecule, neutrophil/macrophage activation inhibitor. It is currently being evaluated in phase 2/3 clinical trials for the treatment of patients with geographic atrophy secondary to macular degeneration.
Lead Product(s): AVD-104
Therapeutic Area: Ophthalmology Product Name: AVD-104
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2024
Details:
AVD-104 is a novel small molecule, classical complement pathway modulator. It is currently being evaluated in phase 2/3 clinical trials for the treatment of patients with geographic atrophy secondary to macular degeneration.
Lead Product(s): AVD-104
Therapeutic Area: Ophthalmology Product Name: AVD-104
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
AVD-104 is an engineered glycan (sialic acid) nanoparticle that reduces inflammation by targeting the self-pattern recognition receptors on overly activated retinal neutrophils. It is under phase 2 clinical development for diabetic macular edema.
Lead Product(s): N-Acetyl-D-neuraminate
Therapeutic Area: Ophthalmology Product Name: AVD-104
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Details:
AVD-104, is an engineered glycan (sialic acid) nanoparticle that targets the self-pattern recognition receptors on overly activated retinal immune cells, which is investigated for the Treatment of Geographic Atrophy from Macular Degeneration.
Lead Product(s): AVD-104
Therapeutic Area: Ophthalmology Product Name: AVD-104
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Details:
AVD-104 is an intravitreal nanoparticle molecule for the treatment of geographic atrophy secondary to macular degeneration, it directly inhibits the activity of damaging phagocytic macrophages and repolarizing them to their resolution state.
Lead Product(s): AVD-104
Therapeutic Area: Ophthalmology Product Name: AVD-104
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2023
Details:
AVD-104 is an intravitreal nanoparticle molecule for the treatment of GA, it directly inhibits the activity of damaging phagocytic macrophages and repolarizing them to their resolution state, and by inhibiting the amplification of the complement cascade.
Lead Product(s): AVD-104
Therapeutic Area: Ophthalmology Product Name: AVD-104
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2023
Details:
The partnership aims to develop next generation of glyco-immune therapeutics. Aviceda’s HALOS™ nanotechnology platform, harnesses the power of glycobiology to modulate the innate immune system to develop next-generation therapeutics, with a focus on immuno-oncology.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Queen’s University Belfast
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 10, 2023
Details:
AVD-104 is an intravitreal nanoparticle molecule for the treatment of GA, it directly inhibits the activity of damaging phagocytic macrophages and repolarizing them to their resolution state, and by inhibiting the amplification of the complement cascade.
Lead Product(s): AVD-104
Therapeutic Area: Ophthalmology Product Name: AVD-104
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Details:
AVD-104 is an intravitreal molecule with a unique dual mechanism of action for the treatment of GA through its modulation of critical inflammatory & complement pathways.
Lead Product(s): AVD-104
Therapeutic Area: Ophthalmology Product Name: AVD-104
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
